Stay current on Braeburn’s latest news by joining our mailing list and never miss a press release.
Braeburn and Knight Therapeutics Announce Filing of PROBUPHINE® in Canada
Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE® in Canada for Opioid Drug Dependence PRINCETON, N.J. and MONTREAL — June 13, 2017 — Braeburn Pharmaceuticals, Inc. (“Braeburn”) and Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Knight’s New Drug Submission (NDS) has been…
Braeburn Pharmaceuticals Names Mike Derkacz as President and CEO
Braeburn Pharmaceuticals Names Mike Derkacz as President and CEO, former Head of CNS and Pain Therapeutics for Teva Pharmaceuticals Braeburn President and CEO, Behshad Sheldon, steps down from Company and Board of Directors – Princeton, New Jersey — June 5, 2017 Braeburn Pharmaceuticals, Inc. (Braeburn) announced today that Mike Derkacz has been named as President…
Braeburn and Camurus Announce Positive Top-line Results from CAM2038 Safety Study
Princeton, New Jersey and Lund, Sweden — 2 May 2017 — Braeburn Pharmaceuticals and Camurus (NASDAQ STO: CAMX) today announced positive top-line results from a long-term Phase 3 trial supporting the safety and efficacy of CAM2038 (weekly and monthly buprenorphine depots) in patients with moderate-to-severe opioid use disorder. “The positive results from this study, coupled…
- « Previous
- 1
- …
- 6
- 7
- 8